Ansaid patent extension
Executive Summary
Provision to extend the patent term of Upjohn's nonsteroidal anti-inflammatory drug by 5-1/2 years was deleted from Senate medical device legislation during the evening of Oct. 12. Sen. Metzenbaum (D-Ohio) supported the device law amendments (S 3006) but was determined to maintain a hold on the bill until the Ansaid provision was removed. S 3006 is now expected to proceed to the Senate floor by early in the week of Oct. 15.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.